News
Recent Advances
CITN and ION operate with a singular strategic focus on testing promising immunotherapy agents and advancing them into the clinic to treat patients. Our trials have been the basis for groundbreaking therapies that have changed the standards of care for two cancers: Merkel cell carcinoma (a rare skin cancer) and T-cell lymphoma (the most common blood cancer). Immunotherapy agents are now recommended for the treatment of patients with these diseases.
Treating Merkel Cell Carcinoma
Treating T-cell Lymphoma
Clinical Trials for People with HIV
Clinical Trials for Children
Treating Merkel Cell Carcinoma
Immunotherapy in the form of a class of compounds known as check-point inhibitors are now recommended to treat Merkel cell carcinoma, a rare form of skin cancer. It has been effective in some people with advanced disease who have not responded to other treatments. For example, twenty-three patients had at least one documented radiologic or clinical assessment of response. Fifteen of 23 evaluable patients (65%) responded (4 complete responses and 11 partial responses). Two additional patients had stable disease and 6 had progressive disease as best response.
Fred Hutch mourns sudden loss of Dr. Martin ‘Mac’ Cheever
Dr. Martin 'Mac' Cheever, cancer immunotherapy expert, receives distinguished service award
Breaking down HIV exclusions in cancer clinical trials
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Meet Global Oncology's deputy program head
For cancer patients with HIV, immunotherapy appears safe
Immunotherapy trial in rare skin cancer named one of 2016’s major advances in clinical cancer research and care
'Finally showing hope': Immunotherapy trial results transforming care for rare skin cancer
6 questions in cancer immunotherapy
Scratching the surface of a rare skin cancer
Media Contact
The Cancer Immunotherapy Trials Network (CITN) and Immune-Oncology Network (ION) strive to make promising experimental immunotherapies broadly available to people with cancer. The goal of immunotherapy is to unleash a patient’s own immune system, enabling it to fight cancer.
We focus on testing novel agents in innovative clinical trials. Our trials are designed to provide critical data that helps speed potential therapies from experimental stages to wide-spread use treating patients with cancer.
We employ the collective expertise of top academic immunologists to design and conduct cancer trials with the most promising immunotherapy agents prioritized for high potential in treating cancer, in collaboration with the National Cancer Institute, foundation, and industry partners.